Core Viewpoint - The company, Xinwei Medical-B (06609), has seen its stock price increase by over 12%, currently trading at HKD 56.55, with a transaction volume of HKD 2.8647 million. The company anticipates significant revenue growth and profitability improvements in the coming years [1]. Financial Performance - Xinwei Medical expects to achieve revenue between approximately RMB 400 million to RMB 410 million for the fiscal year ending December 31, 2025, representing a year-on-year increase of at least 43.9% [1]. - The company forecasts a pre-tax profit of approximately RMB 80 million, indicating a turnaround from previous losses [1]. Growth Drivers - Revenue growth is primarily attributed to the launch of new products and technologies for ischemic stroke, an increase in market share for ischemic stroke products, and the commercialization of intracranial stents [1]. - Continued sales growth in interventional access products and effective cost control measures have contributed to a reduction in expense ratios [1]. Product Development - Xinwei Medical announced that its self-expanding intracranial drug-eluting stent registration application has been accepted by the National Medical Products Administration. This product is designed for the treatment of intracranial atherosclerotic stenosis, providing support and patency to narrowed and obstructed lumens while effectively preventing in-stent restenosis [1]. - Currently, there are no similar products approved for market globally, positioning the company at the forefront of this product development within the industry [1].
港股异动 | 心玮医疗-B(06609)涨超12% 预计2025年除税前利润约8000万元 同比扭亏为盈